Etanercept biosimilar (Bionovis/The Instituto Vital Brazil)

依那西普生物类似药 (Bionovis/The Instituto Vital Brazil)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEtanercept biosimilar (Bionovis/The Instituto Vital Brazil)
Drug Alias Name依那西普生物仿制药 (Bionovis/The Instituto Vital Brazil)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor β inhibitorsTumor necrosis factor α inhibitors
TargetsTumor necrosis factor βTumor necrosis factor α
Therapy Area/IndicationsPsoriasisArthritis, RheumatoidSpondylitis, Ankylosing +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Clinical)
Highest Status in ChinaN/A
Originator CompaniesBionovisThe Instituto Vital Brazil
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBionovisThe Instituto Vital Brazil
Active IndicationsN/A
Inactive IndicationsPsoriasisArthritis, RheumatoidSpondylitis, Ankylosing +[4] 

Other Information

ATC CodeL04AB01
Related LinksN/A